{"schema_version":"secwatch.filing_event.v1","accession":"0000728387-26-000003","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.599473+00:00","generated_at":"2026-05-15T12:13:08.637016+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Perspective Therapeutics reports FY2025 net loss $103M; lead program shows durable responses; cash ~$309M post-offering","bullets":["Net loss $103.1M ($1.40/sh) vs $79.3M ($1.23) in FY2024; R&D spend $84.2M (+102% YoY).","Cash $145M at Dec 31, 2025; Feb 2026 equity offering net proceeds ~$164M; runway into late 2027.","VMT-α-NET: 76% progression-free at ~13 weeks additional follow-up; 39% objective response rate in Cohort 2.","Cohort 3 cleared for more patients; all Cohort 2 expected to have ≥48 weeks follow-up by mid-2026.","$10M non-cash impairment for deprioritized preclinical asset; three clinical programs continue."],"urls":{"canonical":"https://secwatch.observer/filing/0000728387-26-000003","json":"https://secwatch.observer/filing/0000728387-26-000003.json","markdown":"https://secwatch.observer/filing/0000728387-26-000003.md","text":"https://secwatch.observer/filing/0000728387-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/0000728387-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/catx-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:13:08.637016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4424f9ee4e2d9d4b7aed246b8f54a4cb2629501","claim":"Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 16, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025 and providing recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/0000728387-26-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}